LRP5 and LRP6 amplification is observed in up to 7.2% and 2.7% of metastatic prostate cancers, yet are relatively infrequent in primary prostate cancer (0–2.1%) (Table 1 and Tables S1–S4). Here, LRP6 is linked to prostate carcinoma.